Zhejiang Hisun Pharmaceutical Co., Ltd.

SHSE:600267 Stock Report

Market Cap: CN¥13.9b

Zhejiang Hisun Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

Zhejiang Hisun Pharmaceutical's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 2.7% annually. Revenues have been declining at an average rate of 5% per year. Zhejiang Hisun Pharmaceutical's return on equity is 7.7%, and it has net margins of 6.8%.

Key information

-3.56%

Earnings growth rate

-5.67%

EPS growth rate

Pharmaceuticals Industry Growth10.90%
Revenue growth rate-4.99%
Return on equity7.71%
Net Margin6.81%
Next Earnings Update26 Aug 2026

Recent past performance updates

Recent updates

Analysis Article • Jan 23

Does Zhejiang Hisun Pharmaceutical (SHSE:600267) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 26

Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business

With a price-to-sales (or "P/S") ratio of 0.9x Zhejiang Hisun Pharmaceutical Co., Ltd. ( SHSE:600267 ) may be sending...
Analysis Article • Apr 30

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 29

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

With a price-to-earnings (or "P/E") ratio of 14.8x Zhejiang Hisun Pharmaceutical Co., Ltd. ( SHSE:600267 ) may be...

Revenue & Expenses Breakdown

How Zhejiang Hisun Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:600267 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2610,3087022,976521
31 Dec 2510,5505412,972479
30 Sep 259,8355473,064467
30 Jun 259,7944653,114383
31 Mar 2510,2455473,096361
31 Dec 2410,3406013,087358
30 Sep 249,547-203,037343
30 Jun 249,556-623,026359
31 Mar 2410,036-773,176384
31 Dec 2310,373-933,281392
30 Sep 2311,9946003,436454
30 Jun 2312,3605743,509458
31 Mar 2312,1235863,427442
31 Dec 2212,0374893,422429
30 Sep 2211,7733193,329395
30 Jun 2211,8695263,402394
31 Mar 2212,0464963,443379
31 Dec 2112,1364873,466373
30 Sep 2112,3085743,540403
30 Jun 2112,0404573,499380
31 Mar 2111,9236143,366403
31 Dec 2011,3544173,355401
30 Sep 2010,914-8193,489726
30 Jun 2010,7242813,626892
31 Mar 2010,774-103,903890
31 Dec 1911,072933,923904
30 Sep 1910,6947553,880780
30 Jun 1910,522-4553,630640
31 Mar 1910,163-4723,418641
31 Dec 1810,187-4923,264640
30 Sep 1810,200162,976468
30 Jun 1810,398152,548633
31 Mar 1810,655182,359526
31 Dec 1710,572142,230439
30 Sep 1710,574-1202,155271
30 Jun 1710,509-1012,4240
31 Mar 1710,090-942,3510
31 Dec 169,733-942,3020
30 Sep 169,396402,2570
30 Jun 168,986-32,2320
31 Mar 168,793152,1830
31 Dec 158,767142,1680
30 Sep 159,382852,3030

Quality Earnings: 600267 has high quality earnings.

Growing Profit Margin: 600267's current net profit margins (6.8%) are higher than last year (5.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600267's earnings have declined by 3.6% per year over the past 5 years.

Accelerating Growth: 600267's earnings growth over the past year (28.4%) exceeds its 5-year average (-3.6% per year).

Earnings vs Industry: 600267 earnings growth over the past year (28.4%) exceeded the Pharmaceuticals industry -1.6%.

Return on Equity

High ROE: 600267's Return on Equity (7.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 08:41
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Hisun Pharmaceutical Co., Ltd. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jing QiangChina International Capital Corporation Limited
Jie YaoCitic Securities Co., Ltd.
Wei DuGoldman Sachs